**Shanghai HeartCare Medical Technology Corporation Limited**
**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

# POSITIVE PROFIT ALERT

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the Group's unaudited consolidated management accounts for the six months ended June 30, 2026 (the "**Reporting Period**") and the information currently available to the Board, the revenue of the Group is expected to be no less than RMB280.0 million for the Reporting Period, representing an increase of at least 50.9%, from the revenue of RMB185.5 million for the six months ended June 30, 2025. The Group also expects to record the net profit of no less than RMB60.0 million for the Reporting Period, representing an increase compared to the net profit of RMB50.9 million for the six months ended June 30, 2025. The Group expects to record the adjusted net profit of no less than RMB70.0 million for the Reporting Period, representing a significant increase of at least 104.7%, from the adjusted net profit of RMB34.2 million for the six months ended June 30, 2025. The Company defines adjusted net profit as net profit excluding the impact of one-off impact of gain or losses relating to the Company's investments. The anticipated increase was mainly attributable to:

— the increase in revenue, which is driven by:

(1) broader recognition of the Group's products among customers, driving continuous growth in end-user demand;

(2) further expansion of the Group's hospital coverage during the Reporting Period; and

(3) rapid revenue growth from the Group's three core business: ischemic stroke, hemorrhagic stroke and vascular closure.

— the increase in adjusted net profit, which is driven by:

(1) increasing revenue contribution from high-margin products, resulting in an improvement in overall gross profit margin compared with the corresponding period of the previous year; and

(2) improvement of operational efficiency, with selling and distribution expenses, and administrative expenses being effectively controlled.

The Company is still in the process of preparing and finalizing the interim results of the Group for the Reporting Period. The data and information contained in this announcement is only a preliminary assessment made by the Board based on the consolidated management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company, and are subject to finalization and adjustments. The unaudited interim results of the Group for the Reporting Period, which is expected to be published by the end of August 2026, may differ from the data and information contained in this announcement.

**Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.**

By order of the Board
**Shanghai HeartCare Medical Technology Corporation Limited**
**WANG Guohui**
*Chairman of the Board*

Shanghai, July 21, 2026

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*